Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628885 | 0.92 | HPGD (0.43) | KMT2ACYP3A4KDM4EALDH1A1XDH | |
| SCHEMBL4515035 | 0.79 | FKBP1A (0.44) | KMT2ACYP3A4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL23657877 | 0.70 | NPC1 (0.53) | KMT2AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL10189678 | 0.69 | ADRB3 (0.41) | KMT2AKDM4EALDH1A1MMP2 | |
| SCHEMBL11964111 | 0.69 | ADRB3 (0.41) | KMT2AKDM4EALDH1A1MMP2 | |
| SCHEMBL1199646 | 0.68 | KMT2A (0.44) | KMT2AALDH1A1SLC6A4MMP2 | |
| SCHEMBL4507031 | 0.68 | SIGMAR1 (0.36) | KMT2ACYP3A4ALDH1A1SLC6A4HPGD | |
| SCHEMBL950990 | 0.68 | KMT2A (0.45) | KMT2AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL23657646 | 0.67 | CNR2 (0.40) | KMT2ACYP3A4KDM4EALDH1A1SLC6A4 | |
| SCHEMBL27070540 | 0.66 | CYP1A2 (0.40) | KMT2ASLC6A4SLC6A2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618983-B2 | Bicyclic triazole α4 integrin inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-11-17 | — | — | US | disclosed |
| US-20060128748-A1 | Bicyclic triazole alpha4 integrin inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128748-A1 | Bicyclic triazole alpha4 integrin inhibitors | ITGA4, ITGB4, ITGB5 | KMT2A 2094/4885CYP3A4 299/4885KDM4E 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.